Q&A: Ace­lyrin CEO Shao-Lee Lin de­tails biotech's $540M IPO, find­ing 'di­a­monds in the rough'

Ace­lyrin start­ed trad­ing on the Nas­daq Fri­day morn­ing in one of the largest biotech ini­tial pub­lic of­fer­ings in re­cent mem­o­ry, with $540 mil­lion in gross pro­ceeds and po­ten­tial­ly $621 mil­lion if un­der­writ­ers ex­er­cise their 30-day op­tion to buy more shares.

End­points News di­aled up Shao-Lee Lin, the Cal­i­for­nia drug de­vel­op­er’s CEO, on Thurs­day night in ad­vance of Ace­lyrin’s $SLRN list­ing, which priced at $18, the high end of its pro­posed range. In a sign of mar­ket ap­petite for the late-stage im­munol­o­gy biotech, Ace­lyrin upped the size of its of­fer­ing twice this week in the lead-up to its de­but, grow­ing from 20.6 mil­lion to 26.5 mil­lion shares be­fore a fi­nal tal­ly of 30 mil­lion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN